The EU approved the Wegovy pill (oral semaglutide 25 mg) on July 15, 2026, its first oral GLP-1 for weight management. Oral Wegovy is FDA-approved in the US.
On July 15, 2026, the European Commission approved the Wegovy pill, a once-daily 25 mg oral semaglutide tablet, as the first oral GLP-1 for weight management across the EU. It treats adults with obesity or overweight plus a comorbidity. Oral Wegovy is already FDA-approved in the United States.
The European Commission has authorized the Wegovy pill, a once-daily 25 mg tablet of oral semaglutide, as the first oral GLP-1 receptor agonist for weight management in the European Union. Novo Nordisk announced the decision on July 15, 2026. This is an EU regulatory action, not a US one. Oral Wegovy was already approved by the US Food and Drug Administration in December 2025, so the pill is FDA-approved in the United States.
Alongside the tablet, the Commission also approved a single, ready-to-use Wegovy 7.2 mg injectable pen, a higher-dose injection for people living with obesity. Both are prescription forms of semaglutide, not aesthetic injectables offered at medspas. Injectable Wegovy is FDA-approved in the US for chronic weight management, but this higher-dose 7.2 mg pen is an EU authorization and is not stated to be FDA-approved.
The European Commission granted marketing authorization for once-daily oral semaglutide 25 mg for adults with obesity (a body mass index of 30 or higher) or overweight (a BMI of 27 or higher) with at least one weight-related comorbidity, used as an adjunct to a reduced-calorie diet and increased physical activity. The decision followed a positive opinion from the European Medicines Agency in May 2026 and makes the tablet the first oral GLP-1 for weight management available across EU member states.
Approval rests on the OASIS 4 trial, a 64-week Phase 3b study of 307 adults with obesity or overweight plus comorbidities. Participants taking oral semaglutide 25 mg lost about 17 percent of body weight on average, compared with about 3 percent on placebo, and roughly one in three reached 20 percent or greater weight loss. The safety profile was consistent with injectable semaglutide, with adverse-event discontinuations of 6.9 percent versus 5.9 percent for placebo. The Commission separately approved a ready-to-use Wegovy 7.2 mg injectable pen, a higher injectable dose.
A daily tablet removes the needle from a class of medicines that has, until now, meant a weekly injection. Novo Nordisk framed the pill as a potentially simpler way to start and continue treatment. For the injectables landscape, it signals that oral delivery of GLP-1 therapy is moving from trials into approved products in two of the world's largest markets.
Regulatory status varies by region and matters here. In the United States, oral Wegovy is FDA-approved and already on the market, and injectable semaglutide (Wegovy) is FDA-approved for chronic weight management. This July 2026 action extends approval to the EU only. Semaglutide of any form is a prescription medicine for obesity and metabolic care, distinct from FDA-approved aesthetic neurotoxins and fillers. It is not an off-label or compounded product in these approved indications, though compounded semaglutide sold elsewhere is a separate, unapproved category.
Watch how quickly the tablet reaches EU pharmacies and how national health systems handle pricing and reimbursement, which the approval itself does not settle. Novo Nordisk has said the product is already available in the United States, Britain, and the UAE, with more country launches planned for the second half of 2026. Also watch prescribing patterns as patients and clinicians weigh a daily pill against a weekly injection.
This report explains a regulatory event and does not recommend starting, stopping, or switching any medication. Decisions about semaglutide or any GLP-1 therapy belong with a licensed prescriber who can assess eligibility, comorbidities, and safety.